Last reviewed · How we verify

I-131 Iodocholesterol — Competitive Intelligence Brief

I-131 Iodocholesterol (I-131 Iodocholesterol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Radiopharmaceutical. Area: Oncology.

phase 3 Radiopharmaceutical Adrenocortical tissue (cholesterol metabolism pathway) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

I-131 Iodocholesterol (I-131 Iodocholesterol) — M.D. Anderson Cancer Center. I-131 Iodocholesterol is a radiolabeled cholesterol analog that localizes to adrenocortical tissue and delivers targeted radiation for imaging and therapeutic purposes in adrenocortical carcinoma.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
I-131 Iodocholesterol TARGET I-131 Iodocholesterol M.D. Anderson Cancer Center phase 3 Radiopharmaceutical Adrenocortical tissue (cholesterol metabolism pathway)
Dexamethasone plus Radium-223 Dexamethasone plus Radium-223 University Health Network, Toronto marketed Combination therapy: corticosteroid plus alpha-emitting radiopharmaceutical Radium-223 targets calcium-mimetic bone uptake; dexamethasone targets glucocorticoid receptor
Tc 99m filtered sulfur colloid Tc 99m filtered sulfur colloid Memorial Health University Medical Center marketed Radiopharmaceutical diagnostic agent
Fludeoxyglucose F 18 (FDG) Fludeoxyglucose F 18 (FDG) Teva Branded Pharmaceutical Products R&D, Inc. marketed Radiopharmaceutical; PET imaging agent Glucose transporter (GLUT1); hexokinase
Radium-223 radium-223 Pfizer marketed Radiopharmaceutical Bone cells
Ga-68-DOTATOC Ga-68-DOTATOC Weill Medical College of Cornell University marketed Radiopharmaceutical Somatostatin receptors (SSTRs) on neuroendocrine tumor cells
Technetium Tc99m Sestamibi Technetium Tc99m Sestamibi Lantheus Medical Imaging marketed Radiopharmaceutical imaging agent Mitochondrial membrane potential

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Radiopharmaceutical class)

  1. Amsterdam UMC, location VUmc · 1 drug in this class
  2. Blue Earth Diagnostics · 1 drug in this class
  3. Brigham and Women's Hospital · 1 drug in this class
  4. Genzyme, a Sanofi Company · 1 drug in this class
  5. Gustave Roussy, Cancer Campus, Grand Paris · 1 drug in this class
  6. HTA Co., Ltd. · 1 drug in this class
  7. IRCCS San Raffaele · 1 drug in this class
  8. ITEL Telecomunicazioni Srl · 1 drug in this class
  9. M.D. Anderson Cancer Center · 1 drug in this class
  10. Michael C Roarke, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). I-131 Iodocholesterol — Competitive Intelligence Brief. https://druglandscape.com/ci/i-131-iodocholesterol. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: